High voluntary alcohol consumption, in experimental liver cirrhosis, is hardly responsive to opioid antagonist treatment

Journal of Physiology and Pharmacology

Volumn 59, Issue 1, 2008, Pages 101-114

  Stasiak, A ^a   Fogel, W A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Liver cirrhosis; Naloxone; Naltrexone; Thioacetamide; Voluntary alcohol intake

Indexed keywords

ALCOHOL; BILIRUBIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; PROTHROMBIN; THIOACETAMIDE;

ALCOHOL CONSUMPTION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; BRAIN CORTEX; CHRONICITY; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG RECEPTOR BINDING; EX VIVO STUDY; EXPERIMENTAL LIVER CIRRHOSIS; FLUID INTAKE; IN VIVO STUDY; LIGAND BINDING; LIGHT DARK CYCLE; LIVER FAILURE; MALE; NONHUMAN; PROTHROMBIN TIME; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; RESPONSE TIME; SCREENING TEST; TREATMENT RESPONSE; URINE VOLUME;

EID: 42049122114     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res Health 2003; 27: 209-219.
2. Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis 2005; 9: 135-149.
3. Reuben A. Alcohol and the liver. Curr Opin Gastroenterol 2007; 23: 283-291.
4. Fogel WA, Andrzejewski W, Maslinski C. Liver damage, voluntary alcohol intake and brain histamine. Agents Actions 1991; 33: 150-153.
5. Fogel WA, Kruk A, Kozlowska M, Sasiak K, Andrzejewski W, Maslinski C. Liver regeneration attenuates increased voluntary alcohol intake evoked by the liver damage. Alcohol Clin Exp Res 1997; 21: 732-737.
6. Fogel WA, Andrzejewski W, Stasiak A, Swendrak-Ameyaw A. Naltrexone and captopril do not modify high preference for alcohol expressed by portocaval shunted rats [abstract]. Acta Neurobiol Exp 1999; 59: 261.
7. Kruk A, Kozlowska M, Kierska D, Sasiak K, Fogel WA. Can liver function improvement by glucagon and insulin therapy modify preference for alcohol caused by the liver cirrhosis? J Physiol Pharmacol 1997; Suppl. 2: 130-136.
8. de Waele J-P, Audet RM, Leong DK, Butterworth RF. Portacaval anastomosis induces region-selective alterations of the endogenous opioid system in the rat brain. Hepatology 1996; 24: 895-901.
9. de Waele J-P, Audet RM, Rose C, Butterworth RF. The portacaval-shunted rat: a new model for the study of the mechanism controlling voluntary ethanol consumption and ethanol preference? Alcohol Clin Exp Res 1997; 21: 305-310.
10. Martin JR, Bircher J, Porchet H. Enhanced ethanol consumption following portal-systemic shunting in rats. Experientia 1982; 38: 814.
11. Martin JR, Porchet H, Bühler R, Bircher J. Increased ethanol consumption and blood ethanol levels in rats with portocaval shunts. Amer J Physiol 1985; 248: G287-G292.
12. Oswald LM, Wand GS. Opioids and alcoholism. Physiol Behav 2004; 81: 339-358.
13. Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J Psychiatry Neurosci 2001; 26: 304-318.
14. de Waele J-P, Kiianmaa K, Gianoulakis C. Distribution of μ and δ opioid binding sites in the brain of the alcohol-preferring AA and alcohol-avoiding ANA lines of rats. J Pharmacol Exp Ther 1995; 275: 518-527.
15. Saland LC, Abeyta A, Frausto S et al. Chronic ethanol consumption reduces delta- and mu-opioid receptor-stimulated G-protein coupling in rat brain. Alcohol Clin Exp Res 2004; 28: 98-104.
16. Heinz A, Reimold M, Wrase J et al. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 2005; 62: 57-64.
17. Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O'Brien CP. A comparison of the effects of the opioid antagonists: naltrexone, naltrindole and beta-funaltrexamine on ethanol consumption in the rat. Alcohol 1998; 15: 281-289.
18. Stromberg MF, Sengpiel T, Mackler SA, Volpicelli JR, O'Brien CP, Vogel WH. Effect of naltrexone on oral consumption of concurrently available ethanol and cocaine in the rat. Alcohol 2002; 28: 169-179.
19. Cichelli MJ, Lewis MJ. Naloxone nonselective suppression of drinking of ethanol, sucrose, saccharin, and water by rats. Pharmacol Biochem Behav 2002; 72: 699-706.
20. Higley AE, Kiefer SW. Delta receptor antagonism, ethanol taste reactivity, and ethanol consumption in outbred male rats. Alcohol 2006; 40: 143-150.
21. 1 or δ opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 2002; 27: 391-399.
22. Kim SG, Stromberg MF, Kim MJ, Volpicelli JR, Park JM. The effect of antagonists selective for mu- and delta-opioid receptor subtypes on alcohol consumption in C57BL/6 mice. Alcohol 2000; 22: 85-90.
23. June HL, Grey C, Warren-Reese C et al. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res 1998; 22: 2174-2185.
24. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2005, 1, Art. No.: CD001867. DOI: 10.1002/14651858.CD001867.pub2.
25. Rezvani AH, Overstreet DH, Mason GA et al. Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. Alcohol Alcohol 2000; 35: 76-83.
26. Sommer W, Hyytiä P, Kiianmaa K. The alcohol-preferring AA and alcohol-avoiding ANA rats: neurobiology of the regulation of alcohol drinking. Addict Biol 2006; 11: 289-309.
27. Overstreet DH, Rezvani AH, Cowen M, Chen F, Lawrence AJ. Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment. Addict Biol 2006; 11: 356-373.
28. Kiefer F, Jahn H, Tarnaske T et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60: 92-99.
29. Drobes DJ, Anton RF, Thomas SE, Voronin K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 2004; 28: 1362-1370.
30. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 2006; 111: 855-876.
31. O'Malley SS, Sinha R, Grilo CM et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res 2007; 31: 625-634.
32. Yurdain C, Li Y, Ha J-H, Jones A, Rothman R. Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonist. J Pharmacol Exp Ther 1995; 273: 185-192.
33. Owczarek D, Garlicka M, Pierzchała-Koziec K, Skulina D, Szulewski P. Met-enkephalin plasma concentration and content in liver tissue in patients with primary biliary cirrhosis. Przegl Lek 2003; 60: 461-466.
34. Ciesla A, Mach T, Pierzchala-Koziec K, Skwara P, Szczepanski W. Met-enkephalin in the liver as a marker of hepatocellular damage in chronic viral hepatitis type B and C. Adv Med Sci 2006; 51: 261-264.
35. Mani AR, Rasool R, Montagnese S, Dehpour AR. Endogenous opioids and liver disease. Scand J Gastroenterol 2006; 41: 1-11.
36. Zimmermann T, Franke H, Dargel R. Studies on lipid and lipoprotein metabolism in rat liver cirrhosis induced by different regimens of thioacetamide administration. Exp Pathol 1986; 30: 109-117.
37. Chilakapati J, Shankar K, Korrapati MC, Hill RA, Mehendale HM. Saturation toxicokinetics of thioacetamide: role in initiation of liver injury. Drug Metab Dispos 2005; 33: 1877-1885.
38. Kato A, Bamba H, Shinohara M, et al. Relationship between expression of cyclin D1 and impaired liver regeneration observed in fibrotic or cirrhotic rats. J Gastroenterol Hepatol 2005; 20: 1198-1205.
39. Popper H. Pathologic aspects of cirrhosis. Amer J Pathol 1977; 87: 228-264.
40. Müller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats-usefulness and reliability of this animal model. Exp Pathol 1988; 34: 229-236.
41. Yin MF, Lian LH, Piao DM, Nan JX. Tetrandrine stimulates the apoptosis of hepatic stellate cells and ameliorates development of fibrosis in a thioacetamide rat model. World J Gastroenterol 2007; 13: 1214-1220.
42. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440-447.
43. Dornay M, Simantov R. Opiate receptors from different tissue sources: solubilization and characterization. J Neurochem 1982; 38: 1524-1531.
44. Courteix C, Bourget P, Caussade F, et al. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics? J Pharmacol Exp Ther 1998; 285: 63-70.
45. Butelman ER, Ko M-C, Sobczyk-Kojiro K, et al. Kappa-opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception. J Pharmacol Exp Ther 1998; 285: 595-601.
46. 3H-methionine enkephalin, an opioid peptide. Eur J Pharmacol 1978; 47: 319-331.
47. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurment with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
48. Murphy JM, McBride WJ, Lumeng L, Li TK. Regional brain levels of monoamines in alcohol-preferring and -nonpreferring lines of rats. Pharmacol Biochem Behav 1982; 16: 145-149.
49. Higley JD, Suomi SJ, Linnoila M. A nonhuman primate model of type II excessive alcohol consumption? Part 1. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations and diminished social competence correlate with excessive alcohol consumption. Alcohol Clin Exp Res 1996; 20: 629-642.
50. Kelaï S, Hanoun N, Aufrére G, Beaugé F, Hamon M, Lanfumey L. Cannabinoid-serotonin interactions in alcohol-preferring vs. alcohol-avoiding mice. J Neurochem 2006; 99: 308-320.
51. Mendez M, Morales-Mulia M. Ethanol exposure differentially alters pro-enkephalin mRNA expression in regions of the mesocorticolimbic system. Psychopharmacology (Berl) 2006; 189: 117-124.
52. Butterworth RF. Hepatic encephalopathy. Alcohol Res Health 2003; 27: 240-246.
53. Celik T, Uzbay T, Cinar K, Bozkaya H, Uzunalimoglu O, Yurdaydin C. Combination treatment of hepatic encephalopathy due to thioacetamide-induced fulminant hepatic failure in the rat with benzodiazepine and opioid receptor antagonists. J Hepatol 1999; 31: 880-886.
54. Thorton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. Brit Med J 1988; 297: 1501-1504.
55. Lee YK, Park SW, Kim YK et al. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol 2005; 40: 297-301.
56. Ferraro FM 3rd, Hill KG, Kaczmarek HJ, Coonfield DL, Kiefer SW. Naltrexone modifies the palatability of basic tastes and alcohol in outbred male rats. Alcohol 2002; 27: 107-114.
57. Kiefer F, Jahn H, Wiedemann K. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry 2005; 38: 184-186.
58. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734-1739.
59. Juarez J, Eliana Bde T. Alcohol consumption is enhanced after naltrexone treatment. Alcohol Clin Exp Res 2007; 31: 260-264.
60. Oslin DW, Berrettini W, Kranzler HR et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546-1552.
61. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr. Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 2006; 30: 1288-1296.
62. Rommelspacher H, Schmidt LG, May T. Plasma norharman (β-carboline) levels are elevated in chronic alcoholics. Alcohol Clin Exp Res 1991; 15: 553-559.
63. Rommelspacher H, Wiest M, Neuhaus R, Platzgummer W, Schmidt LG, Neuhaus P. Long-term changes of markers of alcoholism after orthotopic liver transplantation (OLT). Transplantation 1996; 62: 1451-1455.